CHEMO-FREE FIRST-LINE THERAPY IN FRAIL PATIENTS WHIT MARGINAL AND MANTLE CELLS NON-HODGKIN LYMPHOMA THIS IS THE FUTURE? OUR EXPERIENCE (SIE 2026) - Oct 6, 2026 - Abstract #SP089; "BKT inhibitors(iBKT)in the treatment of some non-Hodgkin's lymphomas are shifting the balance in the therapeutic ap- proach of these diseases,increasingly moving towards che- motherapy-free(f-CHT) treatment.The lymphomas that al- ready have approval for the use of iBKT are mantle cell lym- phoma(mNHL) and marginal lymphoma(MNHL)with good re- sults but used only as monotherapy and from second line.An unmet medical need is how to treat frail elderly pts in the first line with iBTK and without cht.The aim of our study is to treat frail pts diagnosed with mNHL or MNHL with a sin- gle dose of bendamustine 70mg/m2immediately discontin- ued, followed by one weekly cycle of ritux- imab375mg/m2,after which iBKT (zanubrutinib for MNHL and acalabrutinib for mNHL)was added concurrently with immunotherapy (Rituxmab375mg/m2,one dose every 28days for 4administrations).Subsequently, they were revaluated and,if in response,the program includes iBTK and ritux-..."
Clinical • Breast Cancer • Geriatric Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin's Lymphoma • Solid Tumor
|
|
L. Pezzullo; A. Malandrini; A. Gigantiello; L. Settembre; G. Signorile; V. Giudice; C. Selleri
|